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Abstract We studied the activities of the monocyte chemoat-
tractant proteins MCP-l, MCP-2 and MCP-3 on human 
embryonic kidney 293-EBNA cells transfected with the MCP-l 
receptor (CC CKR2B). At 4 nM, MCP-2 induced a CaH influx 
which was as potent as that with MCP-l at 4 nM, although the 
increase by MCP-2 became saturated at higher concentrations. 
In addition, all three MCPs showed dose-dependent inhibition of 
adenylyl cyclase activity stimulated by forskolin (ICso values: 
0.3 nM for MCP-l, 7 nM for MCP-2, and 1.5 nM for MCP-3). 
In conclusion, our data indicate that MCP-2 can exert its effects 
through the MCP-l receptor, CC CKR2B. 
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1. Introduction 
Chemokines have been identified as structurally and func-
tionally related cytokines which have chemotactic activity for 
leukocytes. They are structurally divided into two subfamilies, 
CXC and CC, according to the position of the preserved 
cysteine residues. It has been postulated that chemokines po-
tentially participate at several points in the cell recruitment 
process, such as activation of integrins, chemotaxis and stim-
ulation of the effector functions of leukocytes [1--4]. Recently, 
the importance of chemokines in leukocyte recruitment into 
inflammatory sites has been confirmed in vivo by means of 
gene targeting techniques [5,6]. 
Monocyte chemoattractant protein-I (MCP-I) and two re-
lated CC chemokines, i.e. MCP-2 and MCP-3, have been 
known to have similar activities for monocytes [7-10], T cells 
[11-14], basophils [15,16] and natural killer cells [17-19], while 
it has been reported that MCP-2 and MCP-3, but not MCP-I, 
have chemotactic activity for eosinophils [16]. On the other 
hand, several chemokine receptors which belong to the seven-
transmembrane, G protein-coupled receptor family have been 
cloned [20,21]. Five types of CC chemokine receptor have 
been cloned so far: MIP-la receptor (CC CKRI) [22,23], 
two alternatively spliced MCP-l receptors (CC CKR2A, 2B) 
[24,25], CC CKR3 [26], CC CKR4 [27] and CC CKR5 [28]. 
Several studies have been conducted on interactions between 
the three MCPs and the cloned CC chemokine receptors. 
Thus, MCP-l has been considered to be highly selective for 
CC CKR2B [29], while MCP-3 has been shown to be a func-
*Corresponding author. Fax: (81) (425) 87-5512. 
Abbreviations: MCP, monocyte chemoattractant protein; MIP, 
macrophage inflammatory protein; RANTES, regulated on activation, 
normal T expressed and secreted; EBNA, EB virus nuclear antigen; 
IC5o , concentration giving 50% inhibition 
tionalligand for both CC CKRI and CC CKR2B [30,31]. On 
the other hand, it is still unclear whether MCP-2 can act as a 
functional ligand for either of these CC CKRs in the receptor 
transfected systems [30,31]. 
Here, we report that MCP-2 is also a functional ligand for 
CC CKR2B based on the results in terms of induction of 
Ca2+ influx and inhibition of adenylyl cyclase in CC 
CKR2B-transfected cells. 
2. Materials and methods 
2.1. Chemokines 
Recombinant human MCP-I was obtained using a baculovirus ex-
pression system, as described elsewhere [32]. All other recombinant 
human chemokines. except for MCP-2, were purchased from Pepro-
tech (Rocky Hill, NJ). Recombinant human MCP-2 was purchased 
from R&D Systems (Minneapolis, MN). The baculovirus-expressed 
MCP-I was iodinated by Amersham International pic. (Buckingham-
shire, UK). The specific activity was 2000 Ci/mmol. 
2.2. Cells 
A human embryonic kidney 293 cell line expressing EB virus nucle-
ar antigen-I (EBNAI), designated 293-EBNA cell line, was purchased 
from Invitrogen (San Diego, CAl and maintained in DMEM (Gibco 
BRL) containing 10% heat-inactivated FCS, 80 Ilg/ml gentamicin and 
0.2 mg/ml Geneticin (Gibco BRL). 
2.3. Establishment of a cell line stably expressing the MCP-1 receptor 
The MCP-I receptor cDNA fragment (identical to CC CKR2B 
[24]) cut from the plasmid described elsewhere [25] was ligated into 
the NotI site ofpCEP-4 (Invitrogen). 293-EBNA cells were transfected 
with the plasmid purified with QIAGEN (Diagen) by the Lipofecta-
mine (Gibco BRL) method and selected in DMEM containing 10% 
heat-inactivated FCS, 0.2 mg/ml hygromycin and 0.2 mg/ml Geneticin 
for 2 weeks. Several clones were obtained, and the clone showing the 
highest expression in MCP-I binding experiments was used in this 
study. 
2.4. Measurement of intracellular Ca2+ concentration 
Changes in the intracellular Ca2+ concentration were measured with 
a fluorescent probe, Fura-2, essentially as described elsewhere [25]. 
The transfected 293-EBNA cells growing in log-phase were harvested, 
suspended in HEPES-Tyrode buffer (129 mM NaCI, 8.9 mM 
NaHC03 ,2.8 mM KCI, 0.8 mM KH2P04 , 5.6 mM dextrose, 10 
mM HEPES, 0.8 mM MgCh; pH 7.4) and incubated with I 11M 
Fura-2 AM (Dojindo, Japan) at 37°C for 30 min. The cells were 
washed with HEPES-Tyrode buffer and resuspended (about 5 X 106 
cells/ml) in the same buffer containing I mM CaCho After incubation 
at 37°C for 5 min, 500 III of the cell suspension was placed in a CAF-
100 calcium analyzer (JASCO Corporation, Japan) with continuous 
stirring at 37°C. Samples were excited at 340 nm and 380 nm, and the 
emission at 500 nm was monitored. The data were recorded as the 
relative ratio of fluorescence excited at 340 nm and 380 nm. 
2.5. Measurements of adenylyl cyclase 
The adenylyl cyclase activity of the transfected 293-EBNA cells was 
measured essentially by the method of Myers et al. [29], but the 
amount of cyclic AMP was determined by ELISA as described else-
where [33]. Transfected cells (5 x 105) were incubated at 37°C for 20 
min in 100 III of RPMI 1640 medium containing 10% FCS, I mM 
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3-isobutyl-I-methylxanthine, 10 11M forskolin and various concentra-
tions of chemokines. The reaction was stopped by placing the tubes in 
a heat block at 9SoC for 10 min. The tubes were then clarified by 
centrifugation at 10000 X g for 15 min. The amount of cyclic AMP in 
the supernatant was determined with an ELISA kit (Amersham Inter-
national pic.). 
2.6. Binding experiments 
The transfected 293-EBNA cells growing in log-phase were used for 
binding experiments. Transfected 293-EBNA cells (106 ) in 200 III of 
binding buffer (RPMI 1640 containing I mg/ml BSA and 25 mM 
HEPES; pH 7.4) were incubated at ISoC for I h with 125 pM 
[125I]MCP_I and various concentrations of unlabeled ligands. After 
the incubation, the cells were collected in a centrifuge, washed in 
500 III of PBS containing I mg/ml BSA and collected again. The 
cell-associated radioactivity was counted using a gamma counter. 
3. Results 
3.1. Ca2+ mobilization by MCPs in the MCP-1 receptor 
transfectants 
The changes in the intracellular Ca2+ concentration induced 
by the three MCPs were measured in the CC CKR2B-trans-
fected cells (Fig. I). MCP-l and MCP-3 each increased the 
intracellular calcium concentration in a dose-dependent man-
ner, and MCP-l was more potent than MCP-3. MCP-2 in-
duced as potent a response as MCP-l at 4 nM, although the 
increase by MCP-2 became saturated at concentrations higher 
than 4 nM. It was confirmed that none of the three MCPs 
induced any change in the intracellular Ca2+ concentration in 
the parental 293-EBNA cells (data not shown). 
3.2. Inhibition of adenylyl cyclase by MCPs in the MCP-1 
receptor transfectants 
Since it has been reported that inhibition of adenylyl cyclase 
is also characteristic of the intracellular signal transduction by 
MCPs [30], we examined the effects of the MCPs on the ade-
nylyl cyclase activity induced by forskolin in our transfected 
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Fig.!. Ca2+ mobilization by MCPs in the Fura-2-loaded MCP-I re-
ceptor-transfected 293-EBNA cells. The fluorescence ratio (F3401 
F3S0) was monitored during addition of various concentrations 
(0.8-100 nM) of MCP-I, MCP-2 and MCP-3 at the times indicated 
by the arrows. 
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Fig. 2. Inhibition of adenylyl cyclase in the MCP-I receptor-trans-
fected 293-EBNA cells by MCPs. Cells (5 X 106 ) were stimulated 
with 10 11M forskolin in the presence or absence of various concen-
trations of MCP-I, MCP-2 and MCP-3. The amount of cyclic AMP 
accumulated in the cells was determined by ELISA. The amount of 
cyclic AMP in the absence of MCPs was treated as the 100% con-
trol. Each point is the mean ± S.E.M. of three separate experiments, 
each performed in triplicate. 
cells (Fig. 2). All three MCPs inhibited adenylyl cyclase activ-
ity in a dose-dependent manner. The IC50 values were as 
follows: 0.3 nM for MCP-I, 7 nM for MCP-2, and 1.5 nM 
for MCP-3. Taken together with the results for calcium mo-
bilization, these results indicate that MCP-2 can exert its ef-
fects through CC CKR2B at a physiological concentration. 
3.3. Binding studies on MCPs in the MCP-1 receptor 
transfectants 
Fig. 3A shows the inhibition of [1251]MCP_l binding to the 
receptor transfectants by unlabeled cheme-hnes. MCP-l and 
MCP-3 inhibited [1251]MCP_l binding in a dose-dependent 
manner (IC5Q = 1.5 nM for MCP-l, 12 nM for MCP-3), while 
MIP-la, -113, RANTES and IL-8 did not. On the other hand, 
[1251]MCP_l binding was rather increased as the added con-
centration of unlabeled MCP-2 became higher. With the pa-
rental 293-EBNA cells, as well, a similar increase in [1251]_ 
MCP-l binding was seen to accompany addition of 
unlabeled MCP-2, but not other chemokines (Fig. 3B). 
4. Discussion 
In this study we have shown that MCP-2, as well as MCP-I 
and MCP-3, acts as a functional ligand for the MCP-I recep-
tor, CC CKR2B. Thus, MCP-2 induced a Ca2+ influx and 
inhibited adenylyl cyclase in the CC CKR2B-transfected cells, 
although it was not necessarily more potent than MCP-l and 
MCP-3. It has been controversial whether the intracellular 
signal of MCP-2 can be also transduced by CC CKR2B, 
although it is well established that MCP-3, in addition to 
MCP-l, is a functional ligand for CC CKR2B [30,31]. In 
terms of the ability to induce chemotaxis of either monocytes 
or T cells, which are known to express CC CKR2B [34J, it has 
been reported that MCP-2 is as potent as MCP-\ and MCP-3 
[9,10,13,14]. On the other hand, the signal transduction mech-
anism by which MCP-2 induces chemotaxis in monocytes 
has been reported to be different from that of either MCP-\ 
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Fig. 3. Competition of P25I)MCP_l binding to the MCP-l receptor-
transfected 293-EBNA cells (A) or parental 293-EBNA cells (B) 
with unlabeled chemokines. Cells (I X 106 (A) or 6x 105 (B» were 
incubated at 18°C for 1 h with 125 pM [125I)MCP_l in the presence 
of various concentrations of unlabeled MCP-I, MCP-2, MCP-3, 
MIP-Ia, MIP-I~, RANTES and IL-8. The cell-associated radioac-
tivity was measured. Each point represents the mean ± S.E.M. of 
triplicate measurements. 
or MCP-3 [8]. In addition, previous reports with CC CKR2B-
transfected cells showed that the MCP-l receptor did not 
transduce the intracellular signal of MCP-2 in terms of 
Ca2+ influx or inhibition of adenylyl cyclase even at 500 nM 
[30,31]. Therefore, our present findings on MCP-2 responsive-
ness in our CC CKR2B-transfected cell system contradict 
those earlier studies. This inconsistency may be partly due 
to a difference in either the manner of existence or the number 
of receptors on the transfected cells. 
MCP-2 did not inhibit e25I]MCP-l binding to the CC 
CKR2B-transfected cells; rather, it increased the [125I]MCP_ 
1 binding. There have been several reports showing the anom-
alous binding nature of CC chemokines in the corresponding 
receptor-transfected 293 cell system. Thus, Neote et al. re-
ported that [125I]RANTES binding to the CC CKRl-trans-
fected 293 cells was rather increased by unlabeled RANTES, 
although [125I]MIP-la binding was inhibited by unlabeled 
MIP-la in a dose-dependent manner [22]. It has been also 
reported that [125I]eotaxin failed to show specific binding to 
the CC CKR3-transfected 293 cells [35]. Therefore, we con-
clude that MCP-2 acts as a functional ligand for CC CKR2B, 
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although it did not inhibit [125I]MCP_l binding to CC 
CKR2B-transfected cells. These results also support the con-
cept that either the manner of existence or the number of 
receptors on the cell surface may affect the ligand binding 
properties of the receptor. 
In conclusion, our present data indicate that MCP-2 can act 
as a functional ligand for the MCP-l receptor, CC CKR2B, 
although it did not inhibit [125I]MCP_l binding to the CC 
CKR2B-transfected cells. 
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